Brokerages Expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) to Announce -$0.04 EPS

Wall Street brokerages forecast that Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) will report earnings of ($0.04) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Osmotica Pharmaceuticals’ earnings. The firm is scheduled to issue its next earnings report on Thursday, August 8th.

On average, analysts expect that Osmotica Pharmaceuticals will report full year earnings of ($0.25) per share for the current financial year. For the next year, analysts forecast that the business will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.17) to ($0.06). Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.08). The business had revenue of $57.13 million during the quarter, compared to analysts’ expectations of $53.58 million.

OSMT has been the subject of a number of research reports. Wells Fargo & Co set a $14.00 target price on Osmotica Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 28th. Zacks Investment Research upgraded Osmotica Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 21st. Finally, Barclays initiated coverage on Osmotica Pharmaceuticals in a report on Tuesday. They set an “overweight” rating and a $11.00 target price for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $14.00.

OSMT stock traded up $0.12 during trading hours on Thursday, reaching $2.46. 24,321 shares of the stock were exchanged, compared to its average volume of 160,395. The stock has a market cap of $121.59 million and a PE ratio of -4.82. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. Osmotica Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $9.90.

Hedge funds and other institutional investors have recently made changes to their positions in the company. American International Group Inc. bought a new position in shares of Osmotica Pharmaceuticals in the 4th quarter valued at about $50,000. SG Americas Securities LLC bought a new position in shares of Osmotica Pharmaceuticals in the 1st quarter valued at about $45,000. Acadian Asset Management LLC bought a new position in shares of Osmotica Pharmaceuticals in the 1st quarter valued at about $52,000. Deutsche Bank AG bought a new position in shares of Osmotica Pharmaceuticals in the 4th quarter valued at about $111,000. Finally, Hancock Whitney Corp bought a new position in shares of Osmotica Pharmaceuticals in the 1st quarter valued at about $83,000. Institutional investors own 11.64% of the company’s stock.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Featured Story: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.